Samsung Biologics, AstraZeneca ink manufacturing deal

By The Science Advisory Board staff writers

September 22, 2020 -- Samsung Biologics and AstraZeneca have signed a $330.8 million long-term supply agreement.

Under terms of the deal, Samsung will provide commercial manufacturing of drug substance and drug product for AstraZeneca's biologics under development; Samsung's remuneration could increase to $545.6 million.

The arrangement will boost AstraZeneca's biologics manufacturing capabilities in the Asia Pacific region, AstraZeneca said.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.